公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2009 | National Center of Excellence for Clinical Trials and Research at National Taiwan University Hospital | CHIA-CHI LIN ; CHIH-HSIN YANG ; ANN-LII CHENG ; Chan W.-K.; HONG-NERNG HO | Drug Information Journal | 3 | 2 | |
2019 | Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors | JHE-CYUAN GUO ; CHIA-CHI LIN ; Lin, Chen Yuan; MIN-SHU HSIEH ; HUNG-YANG KUO ; Lien, Ming Yu; YU-YUN SHAO ; Ta-Chen Huang ; CHIH-HUNG HSU | Anticancer research | 28 | 29 | |
2017 | New data on clinical decisions in NSCLC patients with uncommon EGFR mutations | Wu T.; Hsiue E.H.; JIH-HSIANG LEE ; Chia-Chi Lin ; CHIH-HSIN YANG | Expert Review of Respiratory Medicine | 15 | 14 | |
2013 | Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy | Galsky M.D.; Moshier E.; Krege S.; CHIA-CHI LIN ; Hahn N.; Ecke T.; Sonpavde G.; Godbold J.; Oh W.K.; Bamias A. | Cancer | 80 | 72 | |
2017 | Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib | BIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Current Oncology Reports | 19 | 19 | |
2007 | Novel targeted therapies for advanced esophageal cancer | CHIA-CHI LIN ; Papadopoulos K.P. | Diseases of the Esophagus | 12 | 12 | |
2020 | Novel trial designs for early phase clinical trials | CHIA-CHI LIN | Phase I Oncology Drug Development | | | |
2019 | Nuclear Factor-κB Overexpression is Correlated with Poor Outcomes after Multimodality Bladder-Preserving Therapy in Patients with Muscle-Invasive Bladder Cancer | CHIANG, YUN ; Wang, Chung-Chieh; YU-CHIEH TSAI ; CHAO-YUAN HUANG ; YEONG-SHIAU PU ; CHIA-CHI LIN ; CHIA-HSIEN CHENG | Journal of clinical medicine | 8 | 7 | |
2018 | Number of resected lymph nodes and survival of patients with locally advanced esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy | JHE-CYUAN GUO ; CHIA-CHI LIN ; Ta-Chen Huang ; PEI-MING HUANG ; HUNG-YANG KUO ; Chang C.-H.; CHIA-CHUN WANG ; CHIA-HSIEN CHENG ; KUN-HUEI YEH ; CHIH-HUNG HSU ; JANG-MING LEE | Anticancer Research | 12 | 11 | |
2016 | Obesity and outcomes in patients with metastatic urothelial carcinoma | Leiter A.; Doucette J.; Krege S.; CHIA-CHI LIN ; Hahn N.; Ecke T.; Sonpavde G.; Bamias A.; Oh W.K.; Galsky M.D. | Bladder Cancer | 6 | 0 | |
2019 | An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma | El Dika I.; Lim H.Y.; Yong W.P.; CHIA-CHI LIN ; Yoon J.-H.; Modiano M.; Freilich B.; Choi H.J.; Chao T.-Y.; Kelley R.K.; Brown J.; Knox J.; Ryoo B.-Y.; Yau T.; Abou-Alfa G.K. | Oncologist | 75 | 59 | |
2020 | Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma | Si L.; Zhang X.; Shin S.J.; Fan Y.; CHIA-CHI LIN ; Kim T.M.; Dechaphunkul A.; Maneechavakajorn J.; Wong C.S.; Ilankumaran P.; Lee D.-Y.; Gasal E.; Li H.; Guo J. | European Journal of Cancer | 13 | 8 | |
2014 | An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer | Stadler W.M.; Vaughn D.J.; Sonpavde G.; Vogelzang N.J.; Tagawa S.T.; Petrylak D.P.; Rosen P.; CHIA-CHI LIN ; Mahoney J.; Modi S.; Lee P.; Ernstoff M.S.; Su W.-C.; Spira A.; Pilz K.; Vinisko R.; Schloss C.; Fritsch H.; Zhao C.; Carducci M.A. | Cancer | 77 | 73 | |
2017 | Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy | BIN-CHI LIAO ; Chia-Chi Lin ; JIH-HSIANG LEE ; CHIH-HSIN YANG | Lung Cancer | 38 | 35 | |
2011 | Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations | CHIA-CHI LIN ; CHIH-HSIN YANG | Drugs | 10 | 10 | |
2017 | Optimal usage of radium-223 in metastatic castration-resistant prostate cancer | Cha T.-L.; Wu T.T.-L.; Vogelzang N.J.; CHAO-YUAN HUANG ; Huang S.-P.; CHIA-CHI LIN ; Ou Y.-C.; Pang S.-T.; Shen D.H.-Y.; Wu W.-J.; Chang W.Y.-H. | Journal of the Formosan Medical Association | 15 | 14 | |
2017 | Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component | CHIH-HSIN YANG ; Ahn M.-J.; Kim D.-W.; Ramalingam S.S.; Sequist L.V.; Su W.-C.; Kim S.-W.; Kim J.-H.; Planchard D.; Felip E.; Blackhall F.; Haggstrom D.; Yoh K.; Novello S.; Gold K.; Hirashima T.; Chia-Chi Lin ; Mann H.; Cantarini M.; Ghiorghiu S.; Jänne P.A. | Journal of Clinical Oncology | 454 | 443 | |
2008 | Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment | ZHONG-ZHE LIN ; CHIUN HSU ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HUNG HSU ; CHIA-CHI LIN ; ANN-LII CHENG ; PAN-CHYR YANG ; CHIH-HSIN YANG | Lung Cancer | 5 | 1 | |
2018 | Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study | CHIA-CHI LIN ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHAO-CHI HO ; WEI-YU LIAO ; JIH-HSIANG LEE ; TZU-HSIU TSAI ; KANG-YI SU ; MIN-SHU HSIEH ; YIH-LEONG CHANG ; Bai Y.-Y.; DE-RUI HUANG ; Thress K.S.; CHIH-HSIN YANG | The Lancet Respiratory Medicine | 120 | 109 | |
2018 | Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors | BIN-CHI LIAO ; Bai Y.-Y; JIH-HSIANG LEE ; CHIA-CHI LIN ; SHU-YUNG LIN ; YEE-FAN LEE ; CHAO-CHI HO ; JIN-YUAN SHIH ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HSIN YANG ; PAN-CHYR YANG | Journal of the Formosan Medical Association | 11 | 9 | |